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Brian Kornblit,1,2 Tania Masmas,2 Søren L. Petersen,2 Hans O. Madsen,1 Carsten Heilmann,3
Lone Schejbel,1 Henrik Sengeløv,4 Klaus Mu¨ller,3 Peter Garred,1 Lars Vindeløv2,4Several studies have demonstrated that genetic variation in cytokine genes can modulate the immune reac-
tions after allogeneic hematopoietic cell transplantation (HCT). High mobility group box 1 protein (HMBG1)
is a pleiotropic cytokine that functions as a pro-inflammatory signal, important for the activation of antigen
presenting cells (APCs) and propagation of inflammation. HMGB1 is implicated in the pathophysiology of a va-
riety of inflammatory diseases, and we have recently found the variation in the HMGB1 gene to be associated
with mortality in patients with systemic inflammatory response syndrome. To assess the impact of the ge-
netic variation in HMGB1 on outcome after allogeneic HCT, we genotyped 276 and 146 patient/donor pairs
treated with allogeneic HCT for hematologic malignancies following myeloablative (MA) or nonmyeloabla-
tive (NMA) conditioning. Associations between genotypes and outcome were only observed in the cohort
treated with MA conditioning. Patient homozygosity or heterozygosity for the–1377delA minor allele was
associated with increased risk of relapse (hazard ratio [HR] 2.11, P5.02) and increased relapse related mor-
tality (RRM) (P 5 .03). Furthermore, patient homozygosity for the 3814C . G minor allele was associated
with increased overall survival (OS; HR 0.13, P 5 .04), progression free survival (PFS; HR 0.30, P 5 .05) and
decreased probability of RRM (P 5 .03). Patient carriage of the 2351insT minor allele reduced the risk of
grade II to IV acute graft-versus-host disease (aGVHD) (HR 0.60, P 5 .01), whereas donor homozygosity
was associated with chronic GVHD (cGVHD) (HR 1.54, P5.01). Our findings suggest that the inherited var-
iation in HMGB1 is associated with outcome after allogeneic HCT following MA conditioning. None of the
polymorphisms were associated with treatment-related mortality (TRM).
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6/j.bbmt.2009.10.002cytes. In the context of acute graft-versus-host
disease (aGVHD) following allogeneic HCT with
myeloablative (MA) conditioning the pathophysiology
of the initial immunoreactions have been conceptual-
ized into a 3-phase model where tissue damage and
release of pro-inflammatory cytokines, caused by total
body irradiation (TBI) and/or chemotherapy of the
conditioning regimen, activates APCs leading to sub-
sequent proliferation of T lymphocytes enabling
them to damage target cells [1].
The origin of the APCs is thought to be impor-
tant in relation to their ability to induce GVHD or
the graft-versus-tumor (GVT) effect. Patient APCs
are critical for the development of aGVHD and the
GVT effect [2-4], whereas donor APCs are important
for the development and perpetuation of chronic
GVHD (cGVHD) [5,6]. In allogeneic HCT after
nonmyeloablative (NMA) conditioning, the mostly
immunosuppressive conditioning regimen is associ-
ated with lower peritransplant toxicity compared to
MA conditioning [7,8]. In NMA conditioning, tumor239
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GVT effect, and lower incidence of disease progres-
sion has been associated with the development of
cGVHD, independently of aGVHD [9].
High mobility group box 1 protein (HMGB1) is an
ubiquitously expressed [10], highly conserved [11],
25-kDaDNA binding protein [12] that has been identi-
fied as an endogenous damage-associated molecular
pattern (DAMP), whih could be detected in serum
hours after an initial septic insult [13]. HMGB1 has
been implicated in the pathology of a wide variety of
infectious [13-16], noninfectious [17,18], and autoim-
mune diseases, such as primary Sjo¨gren’s disease and
systemic sclerosis [19,20]. In cancer, HMGB1 has
been observed to influence immunogenicity of antigens
presented byAPCs [21], and overexpression ofHMGB1
has been associated with proliferation of cancer cells,
metastasis, and a generally worse prognosis [22-24].
HMGB1 diffuses freely from necrotic cells and is
tightly sequestered in the nucleus of apoptotic cells,
providing an endogenous danger signal for the organ-
ism to distinguish between programmed and nonprog-
rammed cell death [25]. Extracellular HMGB1
exhibits inflammatory cytokine-like activity and acts
as a potent mediator of APC activation [26-28] and
proliferation of T cells [26,29]. As HMGB1 is secreted
by activated immune cells in response to pro-inflam-
matory cytokines, it has an ability to self-amplify and
prolong inflammation [13,30]. Other functions of ex-
tracellular HMGB1 are abrogation of the epithelial
barrier function [31-33] and promotion of tissue repair
and regeneration [34-36]
The humanHMGB1 gene consists of 5 exons, and is
located on the short arm of chromosome 13 [37]. We
have identified several polymorphic loci throughout
the gene [38], and, in a recent study of patients with sys-
temic inflammatory response syndrome (SIRS) admitted
to an intensive care unit, we showed that the–1377delA
and 982C . T polymorphisms were significant risk
factors for late and early mortality, respectively [39].
Genetic variation in cytokine genes can modulate
the immune reactions after allogeneicHCTandhereby
influence the outcome [40]. Because of the pro-inflam-
matory nature ofHMGB1, its central role in the activa-
tion of APCs and our observation that HMGB1
polymorphisms were associated with outcome in
SIRS patients, we hypothesized that theHMGB1 geno-
type of either recipients or donors could influence the
risk of GVHD, relapse, and death in patients treated
with allogeneic HCT. The objective of the current
studywas, therefore, to analyze the association between
HMGB1 genotype andoutcome inpatients treatedwith
allogeneic HCT after 2 different conditioning regi-
mens, namely, MA conditioning, characterized by a
high inflammatory milieu posttransplant, and NMA
conditioning, where the immediate period posttrans-
plant is characterized by a lower state of inflammation.MATERIALS AND METHODS
Patients
The study population consisted of 2 independent
cohorts undergoing allogeneic HCT. One of 276
patients treated with MA conditioning between Janu-
ary 1990 and November 2007, and a second of 146
patients treated with NMA conditioning between
March 2000 and July 2007. Both cohorts were treated
for malignant hematologic disease at the BoneMarrow
Transplantation Unit at Rigshospitalet, Copenhagen,
Denmark. The inclusion criteria were the availability
of pretransplantation blood samples from either
recipients or donors. Patient demographics are listed
in Table 1.
In the MA conditioning cohort, DNA was avail-
able from 275 patients and 274 donors, whereas
DNA from all patients and donors was available in
the NMA conditioning cohort. With improving
HLA-typing techniques the definition of matched
unrelated donors has changed from 1990 to 2007. Pa-
tient-donor pairs from the MA conditioning cohort
that were HLA-typed early in the study period were
typed by a combination of low-resolution serological
typing for HLA-A and HLA-B and high-resolution
genotyping for DRB1, whereas patient donor pairs
HLA-typed later in the study period were high-resolu-
tion genotyped for HLA-A, -B, -C, and DRB1 and
DQB1. All patients and donors in theNMA condition-
ing cohort were matched with high-resolution HLA-
typing for HLA-A, -B, -C, DRB1, and DQB1, and
only a single HLA allele disparity was allowed. For
the purpose of the current study, a matched unrelated
donor was defined, as a donor fully HLA matched
using the typing methods available at the time of trans-
plantation, realizing that the group of patient donor
pairs partially matched with serological techniques
could include high-resolution mismatches.
The diagnoses in the MA conditioning cohort in-
cluded acute lymphoblastic leukemia (ALL; n 5 92),
acute myelogenous leukemia (AML; n 5 93), chronic
myelogenous leukemia (CML; n 5 65), and other he-
matologic malignancies (n 5 26). Acute leukemias in
first remission and CML in first chronic phase (CP1)
were classified as standard risk disease, whereas all
other diagnoses or disease stages as high risk. The di-
agnoses in the NMA conditioning cohort included
AML/myelodysplastic syndrome (MDS; n 5 62),
non-Hodgkin lymphoma (NHL; n 5 30) follicular
lymphoma, (FL; n 5 19); diffuse large B-cell lym-
phoma, (DLBCL; n 5 4); mantle cell lymphoma,
(n 5 4); peripheral T-cell lymphoma (n 5 3), chroni
lymphocytic leukemia (CLL; n 5 21), multiple mye-
loma (MM; n 5 15), Hodgkin disease (HD; n 5 15),
and CML (n 5 3). In the MA conditioning cohort,
7 patients transplanted with a related donor received
Table 1. Pretransplantation Demographics
Variable
Myeloablative
Cohort (N 5 276)
Nonmyeloablative
Cohort
(N 5 146)
Patient age, median years (range) 28 (0.7-57) 53 (19-69)
< 16 years, no. (%) 78 (28) 0
16–40 years, no. (%) 118 (43) 21 (14)
> 40 years, no. (%) 80 (29) 125 (86)
Donor age, median years (range) 35 (0.7-62) 44 (19-68)
< 16 years, no. (%) 33 (12) 0
16–40 years, no. (%) 148 (54) 50 (34)
> 40 years, no. (%) 89 (32) 91 (63)
Not available 6 (2) 5 (3)
Type of donor
Matched related, no. (%) 138 (50) 86 (59)
Mismatched related, no. (%) 11 (4) 0
Matched unrelated, no. (%) 97 (35) 49 (34)
Mismatched unrelated, no. (%) 30 (11) 11 (8)
Sex of patient / donor
Male / female, no. (%) 50 (18) 34 (23)
Other combinations, no. (%) 226 (82) 112 (77)
Underlying disease
Low risk, no. (%) 0 30 (21)
Standard risk, no. (%) 95 (34) 71 (48)
High risk, no. (%) 181 (66) 45 (31)
Conditioning regimen
Cyclophosphamide and
12Gy TBI, no. (%)
155 (56) 0
Etoposide and 12Gy TBI, no. (%) 51 (18) 0
Busulfan and
cyclophosphamide, no. (%)
49 (18) 0
Other conditioning regimens, no.
(%) (20 included
cyclophosphamide)
21 (8) 0
Fludarabine and 2Gy TBI, no. (%) 0 143 (98)*
2Gy TBI, no. (%) 0 3 (2)
Use of ATG in conditioning
No ATG, no. (%) 165 (60) 146
ATG, no. (%) 111 (40) 0
Stem cell source
Peripheral blood, no. (%) 186 (67) 146
Bone marrow, no. (%) 90 (33) 0
Immuno suppression
Cyclosporine alone, no. (%) 41 (15) —
Methotrexate, and
cyclosporine, no. (%)
234 (85) —
Mycophenolate mofetil and
cyclosporine or tacrolimus,
no. (%)
— 146
None 1 —
CMV serostatus of patient / donor
CMV-negative / CMV-negative 69 (25) 31 (21)
Other combinations 203 (74) 115 (79)
Inconclusive CMV serology 4 (1) 0
Pre-transplantation Karnofsky score
100 - 80, no. (%) 260 (94) 68 (47)
< 80, no. (%) 16 (5) 3 (2)
Not available 0 75 (51)
TBI indicates total body irradiation; CMV, cytomegalovirus; ATG, antith-
ymocyte globulin.
In the cohort treated with myeloablative conditioning, standard risk was
defined as acute leukemia in first remission and chronic leukemia in first
chronic phase, whereas all other diseases and stages were considered
high risk. The diseases in recipients treated with nonmyeloablative con-
ditioning were classified as low, standard, or high risk according to Kahl
et al. [67].
*Includes 1 patient who was conditioned with 3 Gy TBI and fludarabine.
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globulin (ATG), whereas all, except 23, transplanted
with an unrelated donor received ATG. ATG was ad-ministered in the form of ATGAM (20 mg/kg/day) or
Thymoglobulin (2.5 mg/kg/day) for 3 days (day–5,
24, and–3 before transplantation). One patient in
theMA conditioning cohort received an ex vivo T lym-
phocyte-depleted bone marrow (BM) from a fully
HLA-matched related donor. The conditioning regi-
men and prophylactic antibiotics employed in the
NMA conditioning cohort has been described previ-
ously [41]. aGVHD and cGVHD were diagnosed ac-
cording to standard criteria [42,43].
Informed consent was obtained from all patients
and the local ethics committee approved the study.
Genotyping
Reference single nucleotide polymorphism num-
bers (rs) are provided for all polymorphisms. The
–1615A . G (rs1412125), 21377delA (rs41369348),
1747delT (rs55946320), 1888insT (rs41497949), and
2351insT (rs41376448) polymorphisms were geno-
typed by direct sequencing as previously described
[39]. The 3814C . G (rs2249825), 982C . T
(rs1060348), and 1177 G . C (rs3742305) polymor-
phisms were genotyped using a 12-plex format
GenomeLab SNPstreamGenotyping system (Beckman
Coulter Inc., Fullerton, CA). For each of the polymor-
phism genotyped by the SNPstream system, the geno-
types, in 10 to 20 samples, were validated by direct
sequencing as previously described [38]. Figure 1 is
a schematic drawing of the HMGB1 gene locus, show-
ing the location of the genetic variants in relation to
each and their exons. For each genetic variant, the allele
with the lowest frequencywill be referred to as theminor
allele, whereas the allele with the highest frequency will
be referred to as the major allele (Table 2).
Statistics
The inferred haplotypes and linkage disequilib-
rium (LD), expressed as D’Lewontin’s coefficient and
squared correlation (R2) coefficient quantified between
all pairs of biallelic loci, were estimated using SNPA-
lyze version 4.0 (Dynacom, Yokohoama, Japan). The
Hardy-Weinberg equilibrium (HWE) was analyzed
using gene frequencies obtained by simple gene count-
ing and the chi-squared test with Yates’ correction.
Fisher’s exact test was used to compare frequencies.
To maximize power, inferred haplotypes, LD and
HWE, were analyzed separately for patient and donor
groups, with each group consisting of patients or
donors from the MA conditioning and NMA condi-
tioning cohorts. As the 982C . T polymorphism has
been previously associated with mortality [39], associ-
ation analyses were performed despite a low minor al-
lele frequency, whereas the 1888insT and 1747delT
polymorphisms were excluded from further analyzes
because of minor allele frequencies\5 % (Table 2).
Because of sporadic failed genotypes during
Figure 1. Schematic illustration of the high mobility group box 1 protein gene locus with exon I to V, marked as solid boxes, and the approximate
location of the genetic variants. The most common inferred haplotypes (frequency.3%), called H1 to H4, in patients and donors are shown. Modified
from Ferrari et al. [37].
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haplotypes (Table 2), association analyzes between
haplotypes and transplantation outcome were not per-
formed. Cox regression was used to estimate the asso-
ciation between HMGB1 genotypes and overall
survival (OS), progression free survival (PFS), relapse
incidence (RI), relapse-related mortality (RRM), treat-
ment-related mortality (TRM), grade II to IV
aGVHD, grade III to IV aGVHD, limited or
extensive cGVHD, and extensive cGVHD. OS was
measured from the time of transplantation until death
from any cause. Patients still alive at the time of anal-
ysis were censored at the date of last follow-up. PFS
was calculated from date of transplantation to date of
first relapse or death. Patients who were alive and in
remission where censored at date of last follow-up.
TRM was defined as death in complete remission or
death related to transplantation where it was not pos-
sible to assess disease status before death. RRM was
defined as death during relapsed or progressive dis-
ease. Probability of OS and PFS were estimated by
the Kaplan-Meier method, and comparisons were
made with the log-rank test. In the calculation of
cumulative incidences for RI, RRM, TRM, and
GVHD, death before relapse, death with or without
relapse, death without GVHD, and retransplantation
were handled as competing events, where appropriate
in these analyzes [44]. Comparisons of cumulative in-
cidences were performed using Gray’s k-sample test
[45]. For the purpose of Cox regression, competing
events were censored. Multivariate Cox regression
models were used to evaluate the risk associated with
HMGB1 polymorphisms on transplantation outcome.
Each covariate listed inTable 1 and grade 2-4 aGVHD
and limited or extensive cGVHD as posttransplanttime-dependent covariates, were entered 1 by 1 in
a pair wise model together with HMGB1 genotype.
The covariates were kept in the final model if they re-
mained significant (P # .05) or altered the association
with the HMGB1 variant by more than 10%. All P-
values were 2-tailed, and P # .05 was considered sig-
nificant.RESULTS
Genetic Variation in the HMGB1 Gene
The HWE, LD, and haplotype inference was ana-
lyzed for recipients and donors separately in a com-
bined MA conditioning and NMA conditioning
cohort. All polymorphisms adhered to the HWE (P
. .05), except for 1747delT (P5 .03) because of 1 in-
dividual homozygous for the minor allele, which was
confirmed by both forward and reverse sequencing.
In the pairwise investigation of LD between the 8
polymorphic loci the strongest squared correlation co-
efficients were between 3814C.G, 1177 G. C, and
2351insT (R2 0.7869- 0.9339) in both recipients and
donors (data not shown). Of 55 and 42 possible in-
ferred haplotypes, the 4 most common accounted for
90% of the chromosomes in both donors and recipi-
ents (Figure 1). There were no significant differences
in the distribution of genotype frequencies between re-
cipients and donors in the separate MA conditioning
and NMA conditioning cohorts (Table 2).Transplantation Outcome
In the cohort of patients who underwent MA con-
ditioning HCT, the median follow-up time was 1190
Table 2. Distribution of Genotypes
Myeloablative Conditioning (N 5 276)
Patients Donors
Polymorphism rs Number Major Allele A Minor Allele a Failed Genotypes (%) A Allele Freq. a Allele Freq. AA Aa aa Failed Genotypes (%) A Allele Freq. a Allele Freq. AA Aa aa
21615A > G 1412124 A G 3 0.51 0.49 0.27 0.48 0.25 2 0.51 0.49 0.26 0.49 0.25
21377delA 41369348 A — 2 0.95 0.05 0.9 0.095 0.005 2 0.95 0.05 0.9 0.095 0.005
1747delT 55946320 T — 2 0.98 0.02 0.97 0.025 0.005 2 0.98 0.024 0.95 0.05 0
1888insT 41497949 — T 1 0.995 0.005 0.99 0.01 0 2 0.998 0.002 0.995 0.005 0
3814C > G 2249825 C G 4 0.72 0.28 0.52 0.40 0.08 3 0.7 0.3 0.47 0.46 0.07
982C > T 1060348 C T 2 0.98 0.02 0.96 0.04 0 2 0.98 0.02 0.96 0.04 0
1177G > C 3742305 G C 1 0.73 0.27 0.53 0.39 0.08 2 0.71 0.29 0.49 0.44 0.07
2351insT 41376448 — T 2 0.74 0.26 0.56 0.37 0.07 2 0.73 0.27 0.52 0.42 0.06
Nonmyeloablative Conditioning (N 5 146)
Patients Donors
Polymorphism rs Number Major Allele A Minor Allele a Failed Genotypes (%) A Allele Freq. a Aallele Freq. AA Aa aa Failed Genotypes (%) A Allele Freq. a Allel Freq. AA Aa aa
21615A > G 1412124 A G 0 0.46 0.54 0.22 0.48 0.3 0 0.52 0.48 0.27 0.22 0.51
21377delA 41369348 A — 0 0.98 0.02 0.95 0.05 0 0 0.95 0.05 0.89 0.11 0
1747delT 55946320 T — 3 0.98 0.02 0.95 0.05 0 3 0.99 0.01 0.97 0.03 0
1888insT 41497949 — T 2 0.99 0.01 0.98 0.02 0 1 0.99 0.01 0.98 0.02 0
3814C > G 2249825 C G 0.5 0.72 0.28 0.54 0.37 0.09 1 0.77 0.23 0.62 0.3 0.08
982C > T 1060348 C T 0 0.97 0.03 0.95 0.05 0 0 0.97 0.03 0.94 0.06 0
1177G > C 3742305 G C 0 0.72 0.28 0.53 0.1 0.37 0 0.76 0.24 0.6 0.32 0.08
2351insT 41376448 — T 1 0.71 0.29 0.54 0.34 0.12 0.5 0.76 0.24 0.6 0.32 0.08
Rs number indicates reference single nucleotide polymorphism number.
Observed frequencies of HMGB1 genotypes in patients and donors according to type of conditioning. There were no significant differences in genotype frequencies between patients and donors in their respective
cohorts (all P > .05). The minor alleles were defined as the alleles with the lowest frequencies, whereas the major alleles were defined as the alleles with the highest frequency.
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100 probability of grade II to IV, and 3 years probabil-
ity of cGVHD were 68%, 58%, 40%, and 40%, re-
spectively. In the NMA conditioning HCT cohort,
the median follow-up was 887 days (range: 30-3229),
and the 5 years OS, PFS, 1-year probability of grade
II to IV aGVHD, and 3 years probability of cGVHD
were 48%, 46%, 66%, and 54%, respectively.
As no significant associations were observed in the
in the NMA conditioning cohort, only genotype asso-
ciation data from the MA conditioning cohort will be
presented. However, results from theNMA condition-
ing cohort corresponding to the main findings in the
MA conditioning cohort are shown in parallel in
Tables 3, 5, and 6. No data concerning the 21615A
. G and 982C . T genotypes will be presented, as
no significant associations with transplant outcome
were observed.
Association of Patient HMGB1–1377delA
Genotype with Relapse
Patient heterozygosity or homozygosity for the–
1377delA minor allele was an independent risk factor
significantly associated with increased RI both in the
unadjusted (P5 .02) (Table 3) and adjustedCox regres-
sion analyzes (P5 .02) (Table 4), whereas only a trend
toward increased RRM was observed (P 5 .05)
(Table 3). The incidence rates of RI (P 5 .01) and
RRM (P 5 .03) stratified according to the–1377delA
genotype were significantly higher in patients carrying
the–1377delA minor allele (Figure 2). There were no
significant associations between patient or donor geno-
type and any other transplantation outcome (Table 3).
Association of Patient HMGB1 3814C . G, 1177
G.Cand 2351insTGenotypewithOS, PFS, and
aGVHD
In general, the 3 polymorphisms, 3814C . G,
1177G.C, and 2351insT tended to have the same in-
fluence on transplantation outcome, because of a mod-
erate to strong LD (R25 .7869-0.9339) between the 3Table 3. Univariate Cox Regression Analyzes According to the Pat
Myeloablative Conditioning
Outcome HR† 95% CI
Overall survival 1.26 0.65-2.45
Progression-free survival 1.43 0.81-2.51
Relapse incidence 2.08 1.11-3.88
Relapse-related mortality 2.14 0.99-4.61
Treatment-related mortality 0.477 0.12-1.98
HR indicates hazard ratio; CI, confidence interval.
*P < .05.
†HR was analyzed with patients homozygous for the HMGB1–1377delA major
A/A, n 5 139) as reference group, compared to patients heterozygous or ho
n 5 27; NMA conditioning cohort A/2 or 2/2, n 5 7).
‡Cox regression was not possible, as no patients homozygous or heterozygou
cumulative incidence was calculated, which yielded P 5 .20.loci. Patient homozygosity for the minor allele of
3814C . G was the strongest independent protective
factor associated with increased OS and PFS, both in
the unadjusted (OS: P 5 .04; PFS: P 5 .02) (Table 5)
and adjusted (OS: P 5 .04; PFS: P 5 .05) Cox regres-
sion analyses (Table 4). Furthermore, patient homozy-
gosity for the minor allele of 3814C . G showed
a trend toward lower RI in the unadjusted Cox regres-
sion analysis (P 5 .06) (Table 5). The probabilities of
OS, PFS, RI, and RRM, were significantly superior
in patients homozygous for the 3814C . G minor
allele, with no observed deaths because of relapse
(Figure 3).
Although, all 3 polymorphisms (3814C.G, 1177
G . C, and 2351insT) showed the same tendency
toward patient heterozygosity decreasing the risk of
grade II to IV aGVHD, only the 2351insT polymor-
phism was significant at the .05 level (Table 5). As the
probability of developing grade II to IV aGVHD was
similar in patients carrying the 2351insT2/T andT/T
genotypes (2351insT: 2/2 47%, 2/T 32%, and T/T
36%), they were analyzed together in both unadjusted
(data not shown) and adjusted Cox regression models,
which showed that carriage of the 2351insT minor
allele was an independent factor reducing the risk of
grade II to IV aGVHD (P 5 .01) (Table 4).Association of DonorHMGB1 3814C.G, 1177G
. C, and 2351insT Genotype with cGVHD
The cumulative incidence of developing limited or
extensive cGVHD showed a successive increase with
the donor carrying 0, 1, or 2 minor alleles of the
3814C . G, 1177 G . C, and 2351insT polymor-
phisms, implying a gene dosage effect (Figure 4, only
2351insT shown). Table 6 shows the results of the uni-
variate Cox regression analyzes, where the 3814C .
G, 1177 G . C, and 2351insT polymorphisms were
analyzed as quantitative variables (0, 1, and 2 minor al-
leles). For all 3 polymorphisms, the HR, denoting the
risk of developing limited or extensive cGVHD per
unit of time per minor allele, was significantlyient–1377delA Genotype
Nonmyeloablative Conditioning
P HR† 95% CI P
.49 0.33 0.05-2.37 .27
.22 0.56 0.14-2.27 .41
.02* 0.46 0.06-0.36 .44
.05 NA‡
.31 0.68 0.09-5.04 .71
allele (MA conditioning cohort A/A, n5 245; NMA conditioning cohort
mozygous for the minor allele (MA conditioning cohort A/2 or 2/2,
s for the minor allele experienced relapse-related mortality. Instead, the
Table 4. Multivariate Cox Regression Analyzes of the Association of HMGB1 Genotype with Transplantation Outcome in the
Cohort Treated with Myeloablative Conditioning
Outcome Covariate HR 95% CI P
Relapse incidence Patient -1377delA A/A Ref.
A/ 2 and 2 / 2 2,11 1.12-4.00 .02*
Donor age <16 years Ref
16-40 years 0,72 0.22-2.33 .58
> 40 years 1,48 0.45-0.486 .52
Donor type Related Ref
Unrelated 1,34 0.80-2.23 .27
Sex of recipient and donor Male / female Ref.
Other combinations 0,35 0.14-0.88 .03*
Immunosuppression CsA Ref.
CsA + MTX 2,08 0.71-6.10 .18
Grade 2 to 4 acute GVHD No Ref
Yes 0,41 0.22-0.75 <.01*
Limited or extensive chronic GVHD No Ref
Yes 0,33 0.17-0.61 <.01*
Overall survival Patient 3814C > G C/C and C/G Ref.
G/G 0,13 0.02-0.94 .04*
Donor type Related Ref.
Unrelated 1,19 0.71-2.01 .50
Underlying disease Standard risk Ref.
High risk 2,86 1.59-5.15 <.01*
Conditioning Cy + TBI Ref.
Eto + TBI 1,33 0.70-2.53 .39
Bu + Cy 0,80 0.44-1.45 .46
Other combinations 0,75 0.32-1.76 .50
Immunosuppression CsA Ref.
CsA + MTX 1,51 0.64-3.57 .35
Karnofsky score 70-100 Ref.
<70 2,36 1.20-4.66 .01*
Progression-free survival Patient 3814C > G C/C and C/G Ref.
G/G 0,30 0.09-0.98 .05
Underlying disease Standard risk Ref.
High risk 1,69 1.11-2.56 .01*
Immunosuppression CsA Ref.
CsA + MTX 1,93 0.95-3.89 .07
Karnofsky score 70-100 Ref.
<70 2,02 1.04-3.90 .04*
Grade 2 to 4 acute GVHD No Ref
Yes 0,63 0.42-0.94 .02*
Grade 2-4 acute GVHD Patient 2351insT 2/ 2 Ref.
T/T and 2 /T 0,60 0.40-0.90 .01*
Immunosuppression CsA Ref.
CsA + MTX 0.58 035-0.98 .04*
Limited or extensive chronic GVHD Donor 2351insT genotype Increase in HR per T allele 1,54 1.13-2.10 .01*
Patient age <16 years Ref.
16-40 years 2.24 1.09-4.57 .03*
>40 years 2.31 1.06-5.08 .04*
Donor age <16 years Ref.
16-40 years 3.58 0.99-12.90 .05
>40 years 3.24 0.85-12.35 .09
Sex of recipient and donor Male / female Ref.
Other combinations 1,70 1.08-2.68 .02*
Conditioning CY + TBI Ref.
Eto + TBI 1,20 0.70-2.06 .50
BU + CY 0,63 0.34-1.17 .15
Other combinations 0,46 0.13-1.59 .22
Stem cell source Peripheral blood Ref.
Bone marrow 1,34 0.89-2.04 .16
Immunosuppression CsA Ref.
CsA + MTX 0.99 0.47-2.10 .98
CMV serostatus of recipient and donor CMV negative/CMV negative Ref.
Other combinations 1,54 0.93-2.56 .10
HR indicates hazard ratio; CI, confidence interval; Ref, reference group; CsA, cyclosporine; MTX, methotrexate; GVHD, graft-versus-host disease; Cy,
cyclophosphamide; TBI, total body irradiation; Eto, etoposide; Bu, busulfan.
The covariates in the table have only been included in the final models, if they changed the estimate of the polymorphisms of interest by at least 10% or
were significantly associated with outcome in pair wise analyzes.
*P < .05.
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Figure 2. Cumulative incidence of relapse incidence and relapse related mortality according to patient 21377delA genotype in the transplantation
cohort treated with myeloablative conditioning. Gray’s k-test between patients with A/A genotype versus patients with A/2 or 2/2 genotypes.
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cGVHD. The 2351insT polymorphism was also eval-
uated as a quantitative variable in a multivariate Cox
regression analysis, where donor carriage of the minor
alleles successively increased the risk of developing
limited or extensive cGVHD significantly (P 5 .01)
(Table 4).
No other significant associations with transplant
outcome were observed (data not shown).DISCUSSION
In the present study we have investigated the asso-
ciation between HMGB1 genotype and outcome after
allogeneic HCT. There were no differences in the dis-
tribution of HMGB1 genotypes between patients and
donors, indicating that the HMGB1 polymorphisms
as such do not play a role in the susceptibility to dis-
eases treated with allogeneic HCT in the present
study. The frequencies of the inferred haplotypes H1
to H4 showed similar distributions compared to the
SIRS cohort and normal population [38,39].
We observed that presence of the minor allele of
the –1377delA polymorphism in patients treated with
allogeneic HCT after MA conditioning, was an inde-
pendent risk factor for RI increasing the probability
of RRM significantly. In a previous study of patients
with SIRS admitted to an intensive care unit, we ob-
served that carriage of the–1377delA minor allele
also was independently associated with mortality
[39]. Although SIRS and allogeneic HCT are different
entities, the confirmative association of this polymor-
phic locus with mortality in 2 independent studies sug-
gests that it is of pathophysiological importance [39].
The 3 polymorphisms 3814C . G, 1777 G . C,
and 2351insT tended to have the same effect on trans-
plantation outcome in the MA conditioning cohort,
because of a moderate to strong LD between loci. Pa-
tient homozygosity for the minor allele of 3814C.G
was the strongest independent factor associated withincreased OS and PFS, and also associated with lower
probabilities of RI and RRM. Patient carriage of the
2351insT minor allele was an independent factor asso-
ciated with decreased risk of grade II to IV aGVHD,
whereas donor carriage of the minor allele displayed
a gene dosage effect, with a successive increase in risk
of developing limited or extensive cGVHD per minor
allele carried. Neither patient nor donor 2351insT ge-
notype was associated with TRM, which is consistent
with the genotype not being independently associated
with grade III to IV aGVHD and extensive cGVHD.
Only associations between HMGB1 genotype and
outcome after allogeneic HCT following MA condi-
tioning but not following NMA conditioning were ob-
served, suggesting a differential effect of HMGB1
depending on the intensity of the conditioning regi-
men. It is generally accepted that the biology of the im-
munoreactions following MA conditioning and NMA
conditioning, in part, differ in respect to the degree of
tissue damage and secretion of inflammatory cyto-
kines, with MA conditioning being more pro-inflam-
matory and tissue damaging [46-48], whereas NMA
conditioning mostly being immunosuppressive. In
the highly pro-inflammatory milieu of MA condition-
ing [46-48], HMGB1 can be passively released by cells
damaged by TBI and/or exposure to cyclophospha-
mide (Cy) [21,49] and actively secreted as in response
to LPS and tumor necrosis factor (TNF)-a [13].
Apart from the conditioning regimen, other differ-
ences between the MA conditioning and NMA condi-
tioning cohorts are present. These pertain to the
patient demographics and are mainly: age at transplan-
tation, type of malignant hematologic disease, stem
cell source, and the HLA-match resolution level, as
all NMA conditioning treated patients had high-
resolution HLA-matching performed. Whether this
heterogeneity also can explain the different impact,
in the 2 allogeneic HCT cohorts, of the HMGB1 poly-
morphisms cannot be excluded.
Collectively, there was a tendency toward patient
HMGB1 genotypes being associated with outcomes
Table 5. Univariate Cox Regression Analyses of Association between Patient HMGB1 Genotype and Transplantation Outcome
Myeloablative conditioning
Outcome
3814 C > G 1177G > C 2351insT
HR (95% CI), P HR (95% CI), P HR (95% CI), P
C/C
(n 5 140) C/G (n 5 107) G/G (n 5 20)
G/G
(n 5 144) C/G (n 5 107) C/C (n 5 21)
2/2
(n 5 150) 2/T (n 5 100) T/T (n 5 20)
Overall survival Ref. 0.99 (0.65 5 1.54) P 5 .99 0.12 (0.02–0.87) P 5 .04* Ref. 1.00 (0.65-1.53) P 5 0.99 0.24 (0.06-0.98) 0.05* Ref. 0.93 (0.60-1.45) P 5 .76 0.26 (0.06-1.01) P 5 .05
Progression-free survival Ref. 1.0 (0.70-1.50) P 5 .91 0.25 (0.08-0.81) P 5 .02* Ref. 1.07 (0.74-1.55) P 5 .73 0.35 (0.13-0.96) P 5 .04* Ref. 1.03 (0.70-1.51) P 5 .88 0.27 (0.08-0.85) P 5 .03*
Relapse incidence Ref. 1.08 (0.67-1.73) P 5 .75 0.26 (0.06-1.07) P 5 .06 Ref. 1.15 (0.72-1.85) P 5 .14 0.42 (0.13-1.35) 0.14 Ref. 1.22 (0.76-1.94) P 5 .41 0.29 (0.07-1.20) P 5 .09
Relapse-related mortality Ref. NA NA Ref. 1.07 (0.60-1.92) P 5 .82 0.23 (0.03-1.67) P 5. 15 Ref. 1.13 (0.63-2.05) P 5 .68 0.25 (0.03-1.83) P 5 0.17
Treatment-related
mortality
Ref. 0.92 (0.49-1.75) P 5 .81 0.26 (0.04-1.96) P 5 .19 Ref. 0.92 (0.49-1.73) P 5 .80 0.25 (0.03-1.87) P 5 .18 Ref. 0.74 (0.38-1.43) P 5 .37 0.24 (0.03-1.80) P 5 .17
Grade II to IV
acute GVHD
Ref. 0.68 (0.45-1.02) P 5 .06 0.72 (0.33-1.57) P 5 .41 Ref. 0.67 (0.44-1.00) P 5 .05 0.69 (0.32-1.50) P 5 .35 Ref. 0.65 (0.43-0.98) P 5 .04* 0.73 (0.34-1.58) P 5 .42
Limited or extensive
chronic GVHD
Ref. 0.83 (0.55-1.25) P 5 .37 1.08 (0.55-2.11) P 5 .83 Ref. 0.89 (0.59-1.34) P 5 .58 0.92 (0.46-1.86) P 5 .82 Ref. 0.88 (0.58-1.33) P 5 .55 1.02 (0.51-2.06) P 5 .95
Nonmyeloablative Conditioning
3814 C > G 1177G > C 2351insT
HR (95% CI), P HR (95% CI), P HR (95% CI), P
Outcome
C/C
(n 5 78) C/G (n 5 54) G/G (n 5 13)
G/G
(n 5 78) C/G (n 5 54) C/C (n 5 14)
2/2
(n 5 78) 2/T (n 5 49) T/T (n 5 17)
Overall survival Ref. 1.19 (0.69-2.07) P 5 .53 1.15 (0.44-2.98) P 5 .78 Ref. 1.23 (0.71-2.13) P 5 .47 1.06 (0.41-2.75) P 5 .91 Ref. 1.08 (0.61-1.90) P 5 .80 1.12 (0.49-2.56) P 5 .79
Progression-free
survival
Ref. 1.02 (0.62-1.69) P 5 .94 0.84 (0.33-2.22) P 5 .72 Ref. 1.05 (0.64-1.74) P 5 .84 0.78 (0.31-1.98) P 5 .60 Ref. 1.04 (0.62-1.74) P 5 .90 0.86 (0.38-1.92) P 5 .71
Relapse incidence Ref. 1.01 (0.52-1.96) P 5 .97 1.16 (0.40-3.38) P 5 .79 Ref. 0.93 (0.48-1.82) P 5 .84 1.02 (0.35-2.96) P 5 .97 Ref. 1.11 (0.57-2.16) P 5 .75 0.85 (0.29-2.47) P 5 .76
Relapse-related
mortality
Ref. 1.41 (0.64-3.09) P 5 1.41 2.16 (0.70-6.74) P 5 .18 Ref. 1.23 (0.56-2.71) P 5 .60 1.83 (0.59-5.62) P 5 .29 Ref. 1.26 (0.57-2.78) P 5 .56 1.40 (0.46-4.30) P 5 .56
Treatment-related
mortality
Ref. 1.02 (0.47-2.22) P 5 .97 0.40 (0.05-2.99) P 5 .37 Ref. 1.22 (0.57-2.64) P 5 .61 0.39 (0.05-2.99) P 5.37 Ref. 0.91 (0.30-2.08) P 5 .82 0.88 (0.25-3.03) P 5 .83
Grade II to IV
acute GVHD
Ref. 0.77 (0.50-1.18) P 5 .23 0.88 (0.42-1.85) P 5 .74 Ref. 0.86 (0.56-1.32) P 5 .49 0.79 (0.38-1.66) P 5 .49 Ref. 1.00 (0.64-1.55) P 5 .98 0.91 (0.48-1.75) P 5 .79
Limited or extensive
chronic GVHD
Ref. 1.30 (0.81-2.09) P 5 .28 1.14 (0.53-2.45) P 5 .74 Ref. 1.16 (0.71-1.88) P 5 .55 1.29 (0.62-2.66) P 5 .50 Ref. 1.30 (0.79-2.14) P 5 .30 1.47 (0.75-2.88) P 5 .27
HR indicates hazard ratio; CI, confidence interval; Ref, reference group; ; GVHD, graft-versus-host disease.
*P < .05.
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Figure 3. Cumulative incidence of OS, PFS, RI, and RRM according to patient 3814C . G genotype in the transplantation cohort treated with mye-
loablative conditioning. Gray’s k-test between patients with G/G genotype versus patients with C/G or C/C genotype.
248 Biol Blood Marrow Transplant 16:239-252, 2010B. Kornblit et al.dependent on primarily patient APCs, such as RI,
RRM, and aGVHD [2-4], and that donor genotypes
were associated with, in part, a donor APC-dependent
outcome, namely, cGVHD [5,6], suggesting that theFigure 4. Cumulative incidence of limited or extensive cGVHD, ac-
cording to donor 2351insT genotype in the transplantation cohort
treated with myeloablative conditioning.polymorphisms in HMGB1 influence the transcription
of HMGB1 in APCs induced by the pro-inflammatory
milieu afterMA conditioning, rather than the passively
released from damaged cells, although these 2 mecha-
nism are not mutually exclusive.
Although we do not yet know the molecular mech-
anisms responsible for the polymorphisms influence
on outcome after allogeneic HCT following MA con-
ditioning, these observations suggest that the–
1377delA, 3814C . G, 1777 G . C, and 2351insT
polymorphisms are important for the function of
HMGB1. As the role of HMGB1 in the setting of allo-
geneic HCT also is unknown, a hypothesis unifying all
the current observations would be premature. The
seemingly close relation between HMGB1 genotype
and relapse-related outcome measures was somewhat
surprising, as associations with aGVHD and TRM
would be expected because of its pro-inflammatory
properties. Nevertheless, the strongest and most con-
sistent observations in the study were associations
with RI, RRM, and cGVHD. In a previous study, scan-
ning of the genomic sequence for pattern matches
against known transcription factor binding motifs re-
vealed that the minor allele of the 3814C . G poly-
morphism created a potential binding site for the
transcriptional enhancer v-Myb [38,50,51], suggesting
Table 6. Cumulative Incidence and Univariate Cox Regression Analyses of Limited and Extensive Chronic Graft-versus-Host
Disease, According to Donor 3814C > G, 1177 G > C, and 2351insT Genotype
Myeloablative Conditioning Nonmyeloablative Conditioning
Cumulative Incidence Cox Regression Cox Regression
Polymorhism Donor Genotype N (%) P HR 95% CI P N HR 95% CI P
3814C > G C/C 129 31 .009* 1.53 1.15-2.05 .004* 89 0.88 0.62-1.24 .451
C/G 123 47 44
G/G 19 58 11
1177G > C G/G 135 31 .005* 1.57 1.18-2.09 .002* 88 0.97 0.69-1.36 .870
C/G 121 48 47
C/C 19 58 11
2351insT 2/ 2 143 32 .004* 1.57 1.17-2.12 .003* 87 1.10 0.79-1.53 .577
2/T 115 47 47
T/T 17 65 11
CI indicates confidence interval; HR, hazard ratio.
In the Cox regression analysis donor 3814C >G, 1177G >C, and 2351insT genotypes were ascribed the value 0, 1, and 2, with respect to the carriage of
0, 1 or 2 minor alleles. The HR denotes the risk per minor allele.
*P < .05.
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and 2351insT, because of LD, could be associated
with increased function of HMGB1. An association
between increased function of HMGB1 and decreased
RI and RRM is supported by recent experiments by
Apetoh et al. [21] and Curtin et al. [52], where tumor
antigen-specific T lymphocyte responses were de-
pendent on HMGB1, as neutralization of HMGB1
abolished immunogenicity of cancer cells in vivo. Fur-
thermore, in amurine tumormodel, tumor growth was
abrogated by using HMGB1 competent fibroblasts as
immunoadjuvants, whereas unabated tumor growth
was observed when fibroblasts unable to release
HMGB1 were used [53]. The association of the
2351insT minor allele with cGVHD is also in coher-
ence with increased function of HMGB1, as increased
extracellular expression of HMGB1 is a feature of
some autoimmune diseases that share clinical features
with cGVHD [19,54,55]. In line with these data, the
association of the–1377delA minor allele with in-
creased RI and RRM, should be associated with de-
creased function of HMGB1. Albeit no
measurements or HMBG1 in plasma or serum were
performed in the present study, no association be-
tween the–1377delA, 3814C . G, 1177 G . C, and
2351insT and serum levels were observed in a previous
study of SIRS patients [39]. The posttranslational
modification of HMGB1 varies depending on whether
it is actively secreted from APCs or passively released
by necrotic cells [56], and it has been suggested that
the biological activity of HMGB1 could vary accord-
ing to these differences [57]. If the genetic variations
in the HMGB1 gene influence the active secretion
from APCs, the effect on outcome could be explained
by changes in the ratio between different subsets of
HMGB1. The presented interpretation of the current
data implies that the polymorphisms influence the
HMGB1-dependent antigen presentation by APCs.
However, the association between the minor allele ofthe 2351insT polymorphism and decreased aGVHD
is in contradiction and cannot readily be explained by
the current model.
Although only the 3814C . G polymorphism
colocated with a potential transcription factor [38],
an influence of the remaining polymorphisms cannot
be ruled out. Genetic polymorphisms can influence
gene expression levels by several mechanisms. Poly-
morphisms found in the regulatory regions can alter
the structure of transcription factor binding sites,
hereby affecting the affinity of the transcriptional
apparatus. In exons and in the exon-intron boundaries
polymorphisms can alter the structure and function of
proteins, by inducing amino acid changes, stop
codons, or altering mRNA splicing and stability. The
2351insT located in the 30-UTR could interfere with
binding of micro-RNA and hereby influence mRNA
stability. Because of strong LD or haplotype effects
the genotyped polymorphisms could also represent
surrogate markers for other distant or yet-unknown
polymorphic loci that influence the gene expression
of HMGB1. The 3814C . G and 1177 G . C poly-
morphisms, which have been genotyped in the Inter-
national HapMap Project [58], are in strong LD with
rs1360485 and rs1045411 also located in the 3-UTR,
although outside the genetic regions sequenced in
our study.
Several non-HLA gene polymorphisms have been
assessed in allogeneic HCT with the most thoroughly
assessed being in TNF-a [40], IL-10 [59-61], IL-6
[62], NOD2/CARD15 [63,64], and mannose binding
lectin [65,66]. Although they have been analyzed in
multiple trials confusion concerning their roles still
exists for most. The impact of non-HLA genetics in
allogeneic HCT after NMA conditioning has recently
been assessed for mannose binding lectin, where no
association was found between genotype and outcome
[66]. The inconsistent and sometimes contradictory
data can to some extent be explained by the
250 Biol Blood Marrow Transplant 16:239-252, 2010B. Kornblit et al.multigeneic regulation of immune responses, where
the pleiotropic effects of cytokines differ depending
on the activating stimuli and timing of activation.
This is further complicated by the heterogeneity in pa-
tient demographics across the different study cohorts
introducing ‘‘noise’’ both genetic and immunobiolog-
ical that can mask influence of the polymorphisms.
With the presented data and proposed model
in mind, an obvious limitation of the current study is
the risk of false-positive associations because of the
numerous comparisons. Although, the significance
level of the discussed results was below .05, the statisti-
cal power of the study was too low to allowmost results
to withstand formal Bonferroni correction, by multi-
plying all P-values by 6. As no corrections for multiple
testingwere applied in the current study, cautious inter-
pretation of the obtained P-values and rigorous valida-
tion of the results in independent cohorts is warranted.
In conclusion, this is the first report of implications
of the genetic variation in the human HMGB1 gene in
a population of patients treated with allogeneic HCT
following MA conditioning. The–1377delA polymor-
phism, which previously has been associated with in-
creased mortality in patients with SIRS was observed
to increase the risk of RI and probability of RRM.
Moreover, 3 polymorphisms in moderate to strong
LD also influenced the risk of relapse related events
and GVHD. Currently, the functional aspects of the
HMGB1 polymorphisms and the role of HMGB1 in
the setting of allogeneic HCT are unknown. However,
HMGB1 is likely to play a role in the development of
GVHD, GVT effect, and possibly engraftment, be-
cause of its central placement in the activation of
APCs and tissue regeneration. Although, the current
study is purely descriptive, our findings suggest that
the inherited variation in the HMBG1 gene locus
could affect outcome after allogeneic HCT following
MA conditioning. Further studies, both clinical, in in-
dependent cohorts, and experimental with in vitro
analysis of the functional relevance of the different
polymorphisms, are needed to confirm these findings
and explain their molecular background.AKNOWLEDGMENTS
Financial disclosure: The authors wish to thank
Anne Bjørlig and Ulla Lang for excellent technical as-
sistance, and the staff of the Department of hematol-
ogy at Rigshospitalet for invaluable help and support.
The work was supported by grants from the Danish
Medical Research council, the Novo Nordisk Re-
search Foundation, The Benzon Foundation, The
Danish Rheumatism Association, The Danish Cancer
Society, Rigshospitalet, and The Lundbeck Founda-
tion. MD, PhD-student Brian Kornblit was supported
by a grant from RigshospitaletREFERENCES
1. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host
disease. Blood Rev. 2003;17:187-194.
2. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of
graft versus host disease by inactivation of host antigen-present-
ing cells. Science. 1999;285:412-415.
3. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells
alone are sufficient to initiate acute graft-versus-host disease. J
Immunol. 2004;172:7393-7398.
4. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R,
Ferrara JL. A crucial role for antigen-presenting cells and alloan-
tigen expression in graft-versus-leukemia responses. Nat Med.
2005;11:1244-1249.
5. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD,
Shlomchik MJ. Distinct roles for donor- and host-derived anti-
gen-presenting cells and costimulatory molecules in murine
chronic graft-versus-host disease: requirements depend on tar-
get organ. Blood. 2005;105:2227-2234.
6. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmu-
nity in graft-versus-host disease. Blood. 2005;105:4885-4891.
7. Baron F, Sandmaier BM. Current status of hematopoietic stem
cell transplantation after nonmyeloablative conditioning. Curr
Opin Hematol. 2005;12:435-443.
8. Baron F, Storb R. Allogeneic hematopoietic cell transplantation
following nonmyeloablative conditioning as treatment for
hematologic malignancies and inherited blood disorders. Mol
Ther. 2006;13:26-41.
9. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor
effects after allogeneic hematopoietic cell transplantation with
nonmyeloablative conditioning. J Clin Oncol. 2005;23:
1993-2003.
10. Bustin M, Lehn DA, Landsman D. Structural features of the
HMG chromosomal proteins and their genes. Biochim Biophys
Acta. 1990;1049:231-243.
11. Vaccari T, Beltrame M, Ferrari S, Bianchi ME. Hmg4, a new
member of the Hmg1/2 gene family. Genomics. 1998;49:247-252.
12. Goodwin GH, Sanders C, Johns EW. A new group of chroma-
tin-associated proteins with a high content of acidic and basic
amino acids. Eur J Biochem. 1973;38:14-19.
13. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator
of endotoxin lethality in mice. Science. 1999;285:248-251.
14. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al.
Persistent elevation of high mobility group box-1 protein
(HMGB1) in patients with severe sepsis and septic shock. Crit
Care Med. 2005;33:564-573.
15. van Zoelen MA, Laterre PF, van Veen SQ, et al. Systemic and
local high mobility group box 1 concentrations during severe in-
fection. Crit Care Med. 2007;35:2999–2804.
16. Gaini S, Koldkjaer OG, Moller HJ, Pedersen C, Pedersen SS. A
comparison of high-mobility group-box 1 protein, lipopolysac-
charide-binding protein and procalcitonin in severe community-
acquired infections and bacteraemia: a prospective study. Crit
Care. 2007;11:R76.
17. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated
high-mobility group box 1 levels in patients with cerebral and
myocardial ischemia. Shock. 2006;25:571-574.
18. Urbonaviciute V, Furnrohr BG,Meister S, et al. Induction of in-
flammatory and immune responses by HMGB1-nucleosome
complexes: implications for the pathogenesis of SLE. J Exp
Med. 2008;205:3007-3018.
19. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-
Herlenius M. Increased extracellular levels of the novel proin-
flammatory cytokine high mobility group box chromosomal
protein 1 in minor salivary glands of patients with Sjogren’s syn-
drome. Arthritis Rheum. 2006;54:2289-2294.
20. Yoshizaki A, Komura K, Iwata Y, et al. Clinical significance of
serumHMGB-1 and sRAGE levels in systemic sclerosis: associ-
ation with disease severity. J Clin Immunol. 2009;29:180-189.
21. Apetoh L,Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-
dependent contribution of the immune system to anticancer
chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
Biol Blood Marrow Transplant 16:239-252, 2010 251Association of HMGB1 Polymorphisms with Outcome after Allogeneic HCT22. Kuniyasu H, Chihara Y, KondoH, Ohmori H, Ukai R. Ampho-
terin induction in prostatic stromal cells by androgen depriva-
tion is associated with metastatic prostate cancer. Oncol Rep.
2003;10:1863-1868.
23. TakadaM,Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of
receptor for advanced glycation end products (RAGE) and
MMP-9 in human pancreatic cancer cells.Hepatogastroenterology.
2004;51:928-930.
24. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of recep-
tor for advanced glycation end products and HMGB1/ampho-
terin in colorectal adenomas. Virchows Arch. 2005;446:411-415.
25. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein
HMGB1 by necrotic cells triggers inflammation. Nature. 2002;
418:191-195.
26. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mo-
bility group box 1 by dendritic cells controls T cell activation via
the receptor for advanced glycation end products. J Immunol.
2005;174:7506-7515.
27. Yang D, ChenQ, Yang H, Tracey KJ, BustinM, Oppenheim JJ.
High mobility group box-1 protein induces the migration and
activation of human dendritic cells and acts as an alarmin. J Leu-
koc Biol. 2007;81:59-66.
28. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-
Querini P. The secretion of HMGB1 is required for the migra-
tion of maturing dendritic cells. J Leukoc Biol. 2007;81:84-91.
29. MessmerD, YangH,TelusmaG, et al. Highmobility group box
protein 1: an endogenous signal for dendritic cell maturation
and Th1 polarization. J Immunol. 2004;173:307-313.
30. Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces
high mobility group box 1 protein release partly through
a TNF-dependent mechanism. J Immunol. 2003;170:3890-3897.
31. Yang R, Harada T,Mollen KP, et al. Anti-HMGB1 neutralizing
antibody ameliorates gut barrier dysfunction and improves sur-
vival after hemorrhagic shock. Mol Med. 2006;12:105-114.
32. Fiuza C, BustinM, Talwar S, et al. Inflammation-promoting ac-
tivity of HMGB1 on human microvascular endothelial cells.
Blood. 2003;101:2652-2660.
33. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ.
HMG-1 as a mediator of acute lung inflammation. J Immunol.
2000;165:2950-2954.
34. PalumboR,BianchiME.Highmobility groupbox 1protein, a cue
for stem cell recruitment. Biochem Pharmacol. 2004;68:1165-1170.
35. De Mori R, Straino S, Di CA, et al. Multiple effects of high mo-
bility group box protein 1 in skeletal muscle regeneration. Arte-
rioscler Thromb Vasc Biol. 2007;27:2377-2383.
36. Palumbo R, Sampaolesi M, De Mori F, et al. Extracellular
HMGB1, a signal of tissue damage, induces mesoangioblast mi-
gration and proliferation. J Cell Biol. 2004;164:441-449.
37. Ferrari S, Finelli P, Rocchi M, Bianchi ME. The active gene that
encodes human high mobility group 1 protein (HMG1) contains
introns andmaps to chromosome 13. Genomics. 1996;35:367-371.
38. Kornblit B, Munthe-Fog L, Petersen SL, Madsen HO,
Vindelov L, Garred P. The genetic variation of the human
HMGB1 gene. Tissue Antigens. 2007;70:151-156.
39. Kornblit B, Munthe-Fog L, Madsen HO, Strom J, Vindelov L,
Garred P. Association of HMGB1 polymorphisms with out-
come in patients with systemic inflammatory response syn-
drome. Crit Care. 2008;12:R83.
40. Dickinson AM. Non-HLA genetics and predicting outcome in
HSCT. Int J Immunogenet. 2008;35:375-380.
41. Kornblit B, Masmas T, Madsen HO, et al. Haematopoietic cell
transplantation with non-myeloablative conditioning in Den-
mark: disease-specific outcome, complications and hospitaliza-
tion requirements of the first 100 transplants. Bone Marrow
Transplant. 2008;41:851-859.
42. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
Conference on Acute GVHDGrading. Bone Marrow Transplant.
1995;15:825-828.
43. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow trans-
plantation. Semin Hematol. 1991;28:250-259.44. Gooley TA, Leisenring W, Crowley J, et al. Estimation of fail-
ure probabilities in the presence of competing risks: new repre-
sentations of old estimators. Stat Med. 1999;18:695-706.
45. Gray RJ. A class of k-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
46. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB.
Effect of total body irradiation, busulfan-cyclophosphamide, or
cyclophosphamide conditioning on inflammatory cytokine
release and development of acute and chronic graft-versus-host
disease in H-2-incompatible transplanted SCID mice. Blood.
1994;83:2360-2367.
47. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L,
Ferrara JL. Total body irradiation and acute graft-versus-host
disease: the role of gastrointestinal damage and inflammatory
cytokines. Blood. 1997;90:3204-3213.
48. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as
a target organ of acute graft-versus-host disease: rationale for the
use of cytokine shields in allogeneic bone marrow transplanta-
tion. Blood. 2000;95:2754-2759.
49. Ditsworth D, Zong WX, Thompson CB. Activation of poly(-
ADP)-ribose polymerase (PARP-1) induces release of the pro-
inflammatory mediator HMGB1 from the nucleus. J Biol
Chem. 2007;282:17845-17854.
50. Hernandez-Munain C, Krangel MS. Regulation of the T-cell
receptor delta enhancer by functional cooperation between
c-Myb and core-binding factors. Mol Cell Biol. 1994;14:473-483.
51. Chayka O, Kintscher J, Braas D, Klempnauer KH. v-Mybmedi-
ates cooperation of a cell-specific enhancer with the mim-1 pro-
moter. Mol Cell Biol. 2005;25:499-511.
52. Curtin JF, LiuN,CandolfiM, et al.HMGB1mediates endogenous
TLR2activationandbrain tumor regression.PLoS Med. 2009;6:e10.
53. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of
apoptotic cells in vivo: role of antigen load, antigen-presenting
cells, and cytokines. J Immunol. 1999;163:130-136.
54. Popovic K, Ek M, Espinosa A, et al. Increased expression of the
novel proinflammatory cytokine high mobility group box chro-
mosomal protein 1 in skin lesions of patients with lupus erythe-
matosus. Arthritis Rheum. 2005;52:3639-3645.
55. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity
post-bone marrow transplantation. Bone Marrow Transplant.
1998;22:873-881.
56. Bonaldi T, Talamo F, Scaffidi P, et al.Monocytic cells hyperace-
tylate chromatin protein HMGB1 to redirect it towards secre-
tion. EMBO J. 2003;22:5551-5560.
57. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-
Querini P. HMGB1: guiding immunity from within. Trends Im-
munol. 2005;26:381-387.
58. The International HapMap Project. Nature. 2003;426:789-796.
59. Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-
10 pathway modulates severity of acute graft-versus-host disease
following hematopoietic cell transplantation: synergism be-
tween IL-10 genotype of patient and IL-10 receptor beta geno-
type of donor. Blood. 2005;106:3995-4001.
60. Azarpira N, Ramzi M, Aghdaie MH, Darai M, Geramizadeh B.
Interleukin-10 gene polymorphism in bone marrow transplant
recipients. Exp Clin Transplant. 2008;6:74-79.
61. Tseng LH, Storer B, Petersdorf E, et al. IL10 and IL10 receptor
gene variation and outcomes after unrelated and related hemato-
poietic cell transplantation. Transplantation. 2009;87:704-710.
62. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH,
Middleton PG. Interferon-gamma and interleukin-6 gene poly-
morphisms associate with graft-versus-host disease in HLA-
matched sibling bone marrow transplantation. Blood. 2001;98:
1594-1600.
63. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient
NOD2/CARD15 mutations associate with transplant-related
mortality and GvHD following allogeneic stem cell transplanta-
tion. Blood. 2004;104:889-894.
64. SairafiD, UzunelM, RembergerM, RingdenO,Mattsson J. No
impact of NOD2/CARD15 on outcome after SCT. Bone Mar-
row Transplant. 2008;41:961-964.
252 Biol Blood Marrow Transplant 16:239-252, 2010B. Kornblit et al.65. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding
lectin gene polymorphisms are associated with major infection
following allogeneic hemopoietic stem cell transplantation.
Blood. 2002;99:3524-3529.
66. Mullighan CG, Heatley SL, Danner S, et al. Mannose-binding
lectin status is associated with risk of major infection followingmyeloablative sibling allogeneic hematopoietic stem cell trans-
plantation. Blood. 2008;112:2120-2128.
67. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients
with malignant diseases given allogeneic hematopoietic cell
transplantation after nonmyeloablative conditioning. Blood.
2007;110:2744-2748.
